HEREDITARY ANGIOEDEMA MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Hereditary Angioedema Market Size and Forecast – 2026-2033

Hereditary Angioedema Market size is estimated to be valued at USD 3.44 Bn in 2026 and is expected to reach USD 6.61 Bn by 2033, exhibiting a compound annual growth rate (CAGR) of 9.8% from 2026 to 2033.

Key Takeaways:

• By Type, Hereditary Angioedema Type I Division will continue leading the market with a share of 68.8% in 2026 due to its greater prevalence along with the existing and diagnostic and treatment pathways.
• By Drug Class, The C1 Esterase Inhibitor Segment is predicted to capture the highest market share of 31.1% in 2026 because of its efficacy and safety profile. It continues to remain first-line therapy in the U.S. for HAE.
• By Route of Administration, Subcutaneous Segment is anticipated to capture the largest market share of 31.1% in 2026 due to the convenience patients have. Subcutaneous self-administered treatments are becoming more popular, especially for managing mild to moderate attacks outside of healthcare settings.
• Regionally, North America is expected to lead the Hereditary Angioedema Market Share of 36.3% in 2026 due to robust reimbursement policies and the high spend volume on advanced biologics.
• Asia Pacific is emerging as the fastest-growing market driven by improving awareness, healthcare infrastructure, and the use of prophylactic and targeted therapies.

Market Overview

Hereditary Angioedema Market Growth expansion is mostly caused by increasing understanding of the condition as well as the introduction of new treatment alternatives. Newer diagnostic tools have resulted in more patients being accurately and earlier diagnosed, which increases the patient population and the need for therapy. Availability of oral dosage forms allows for easy self-administration at home, which is more convenient than traditional injectables. On the other hand, the market faces some challenges concerning the overall high treatment costs that are often associated with these medications which limits access for a number of patients.

Current Events and Its Impact on the Hereditary Angioedema Market

Segmental Insights

Hereditary Angioedema Market Insights by Type- Rising Awareness Boosts hereditary angioedema Type I Segment Growth

In terms of type, hereditary angioedema type I segment is estimated to contribute the highest Hereditary Angioedema Market Demand share of 68.8% in 2026, due to increased awareness about the condition. Rising diagnosis rates and awareness initiatives have encouraged patients with mild symptoms to seek treatment. Advancements in targeted therapy have also improved the management of attacks and adherence to treatment protocols.

Hereditary Angioedema Market Insights by Drug Class- C1 Esterase Inhibitor Maintains Dominance Due to Safety Profile

In terms of Drug Class, the C1 esterase inhibitor segment will lead the Hereditary Angioedema Market Forecast share with 31.1% in 2026 due to its well-established efficacy and safety profile. This class features the first drug approved by the U.S. FDA for the treatment of acute attacks of HAE with self-administered enhancement patient options. The ability of patients to reconstitute and act within 30 minutes empowers them to cope with initial symptom control, further cementing C1 esterase inhibitors' commanding market position.

Hereditary Angioedema Market Insights by Route of Administration- Patient convenience drives the subcutaneous segment growth

In terms of Route of Administration, subcutaneous route of administration will dominate the Hereditary Angioedema Market Outlook by 31.1% share in 2026 due to high patient mobility. The use of self-administered subcutaneous injections has been on the rise among HAE patients, a trend which spares the need for hospital access, relevant to the treatment of mild-to-moderate attacks that happen outside medical facilities.

Regional Insights

North America Hereditary Angioedema Market Analysis and Trends

North America is predicted to have the largest Hereditary Angioedema Market Value controlling an approximate share of 36.3% in 2026. This is attributed to the count of major pharma players in the region, favorable healthcare reimbursement policies, and heightened patient awareness.

Asia Pacific Hereditary Angioedema Market Analysis and Trends

The Asia Pacific region is expected to grow at the fastest rate capturing an approximate market share of 22.9% in 2026. This is due to the evolving healthcare system, better access to medical services, and expansion efforts by other major players in the emerging markets.

Hereditary Angioedema Market Outlook for Key Countries

Launch of innovative therapies in U.S.

Innovative therapies are constantly being introduced in the United States, which is greatly aiding the growth of the Hereditary Angioedema Market Trends. Companies are now focusing precision medicine on individual patients’ needs by investing more in clinical trials to develop treatment regimens through targeted therapies. This shift is important as it leads to the development of next-generation therapies such as oral and injectable subcutaneous medications that are more convenient and easier to follow than existing therapies.

Germany’s favorable national guidelines and funding

The growth of the German hereditary angioedema sector is facilitated by encouraging national policies and support directed toward the management of rare diseases. The German government is bolstering healthcare for rare diseases through its National Action Plan which aims at improving the overall strategy for diagnosis, treatment, and patient management. The partnership of healthcare providers and pharmaceutical companies actively supports the R&D initiatives to develop new therapies for wider use.

Japan’s increasing clinical focus

Focus on Japan's clinical practices regarding HAE has driven marked growth for the region. The increased recognition of HAE among professionals issyndicated by focused marketing promoting the diseases. Pharmaceutical firms are increasingly participating in the campaigns to educate doctors about the signs, identifying methods, and treatment options available for HAE. There is notable development from the market leaders directed at new medicines focused on HAE patients’ needs in the Japan hereditary angioedema market.

China’s government's commitment to enhancing medical access and improving healthcare infrastructure

The expansion of the China hereditary angioedema market is attributed to the growth of investment in the health systems of the country. Medical professionals have been given improved qualifications and extensive access to modern healthcare devices. The reform aims to ensure the entire population can receive medical assistance while solving the issues of healthcare accessibility and quality between urban and rural regions. This goal comes under the wider initiative termed ‘Healthy China 2030’ which aims to provide greater disease prevention.

Latest News on Hereditary Angioedema Market

• On September 3, 2024, KalVista Pharmaceuticals, Inc.\ drug manufacturer, reported that the Food and Drug Administration accepted their New Drug Application for sebetralstat, an investigational oral plasma kallikrein inhibitor that marks is intended for on-demand treatment of HAE attacks in patients aged 12 or older.
• On June 18, 2024, Ionis Pharmaceuticals, Inc, a drug manufacturer, reported entering a licensing agreement with biopharmaceutical company Otsuka Pharmaceutical Co. Ltd granting the latter exclusive donidalorsen rights in the Asia Pacific region. Donidalorsen is an investigational RNA-targeted prophylactic treatment for HAE. This agreement is an expansion of preexisting collaborations allowing Otsuka to pursue the regulatory approval and subsequent commercialization within this significant market.
• On June 18, 2024, KalVista Pharmaceutical, Inc., a drug manufacturer, announced plans to file a New Drug Application with the Food and Drug Administration for sebetralstat. This investigational oral plasma kallikrein inhibitor is intended for on-demand treatment of HAE attacks in adult and pediatric patients 12 years and older.

Market Concentration and Competitive Landscape

Top Strategies Followed by Hereditary Angioedema Market Players

• Dominating players in the hereditary angioedema market put a lot of effort in R&D to provide new treatment methods. Companies such as CSL Behring and Sanofi spend more than 15% of their annual revenue on research and development. These companies aim to provide more precise and powerful therapies in the future that would help alleviate symptoms and reduce the frequency of attacks in the patients.
• Mid-tier manufacturers employed a more pragmatic approach by adopting lower-cost measures as a primary focus. Companies, such as BioCryst and Ionis Pharmaceuticals focus on generating generic and biosimilar medicines at rates 20-30% lower than branded therapies. Their generic medications improve access to treatment in low and middle-income economies. KalVista has formed agreements with large pharmaceutical companies to improve their production capabilities and commercial capabilities.

Market Report Scope

Market Dynamics

Market Driver- Increasing prevalence of hereditary angioedema

The rising prevalence of HAE might cause an increase in economic investment. A systematic review titled “Epidemiology, Economic, and Humanistic Burden of Hereditary Angioedema: A Systematic review” published in 2024 in the Orphanet Journal of Rare Diseases examined more than 65 studies with over 10,000 participants and estimated that the global prevalence of hereditary angioedema (HAE) is between 0.13 to 1.6 cases per 100,000 people in a region. For instance, Austria reported a prevalence of 1.6 per 100,000 while South Korea reported 0.13 per 100,000. Black patients in the US were reported to have a prevalence of 1.64 per 100,000 which is higher than white patients estimated at 1.47 per 100,000

Market Challenge- Missed diagnosis or misdiagnosis

Market opportunity may be restricted by a lack of public understanding about the condition. For example, “What to Know about Hereditary Angioedema (HAE)” is an article published on Health.com in 2025 that discusses the difficulties associated with identifying HAE. Due to its rarity and the shared symptoms of many other diseases, HAE is often misdiagnosed which contributes to further diagnostic delays. The article mentions that patients will likely receive the right diagnosis after a decade or more of having the symptoms which is horrendous to think about. This only

Market Opportunity - Product pipeline for treatment

The developed HAE treatment products can easily be exploited by market competitors through their enhanced effectiveness and broadened range of application. Treatment adherence is improved with the innovation of oral medications and subcutaneous injections, along with next-generation prophylactic and on-demand therapies. The incorporation of long-acting C1 inhibitors and Kallikrein inhibitors are proving to be transformative with self-administered and variable dosing which will significantly enhance the life of the patients suffering from HAE. For example, monoclonal antibodies like garadacimab which targets factor XIIa have been promising for long-term prophylactic treatment. A 2024 study supports the notion of subcutaneous monthly injection due to the enduring safety profile of garadacimab during HAE attacks and overall favorable safety.

Analyst Viewpoint

• Increased awareness and diagnosis of the disease will enable steady growth of the global hereditary angioedema market for the forecasted period. The existing treatment gap along with few approved therapy options underscores the need for advanced therapies with improved effectiveness and ease of administration. Such improvements could make a significant difference in changing the treatment paradigm.
• The absence of disease awareness in emerging countries could impede market growth. Leading pharmaceutical market players have a high opportunity potential to develop novel therapies for the existing treatment gaps. The innovation of subcutaneous and oral dosage forms with better pharmacokinetic profiles would enhance treatment adherence.
• Due to high spending on healthcare and the early adoption of new therapies in the region, North America will continue to dominate the market. However, developed Asian Europe are expected to outperform other countries in the region in terms of growth.

Market Segmentation

• By Type Insights (Revenue, USD Bn, 2021 – 2033)
• • Hereditary Angioedema Type I
  • Hereditary Angioedema Type II
• By Drug Class Insights (Revenue, USD Bn, 2021 – 2033)
  • C1 Esterase Inhibitor
  • Kallikrein Inhibitor
  • Bradykinin Receptor
  • Attenuated Androgens
  • Others
• By Route of Administration Insights (Revenue, USD Bn, 2021 – 2033)
  • Subcutaneous
  • Intravenous
  • Oral
• By Distribution Channel Insights (Revenue, USD Bn, 2021 – 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Regional Insights (Revenue, USD Bn, 2021 – 2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights (Revenue, USD Bn, 2021 - 2033)
  • CSL Behring
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Orchard Therapeutics plc.
  • Pharming Group N.V.
  • BioCryst Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Attune Pharmaceuticals
  • Arrowhead Pharmaceuticals, Inc.
  • Adverum Biotechnologies, Inc.
  • KalVista Pharmaceuticals
  • CENTOGENE N.V.

Sources

Primary Research Interviews

• Key Opinion Leaders (KOLs) in the Hereditary Angioedema field
• Hereditary Angioedema Treatment Providers
• Hereditary Angioedema Patients and Caregivers
• Pharmaceutical Companies
• Others

Databases

• Orphanet
• ClinicalTrials.gov
• National Organization for Rare Disorders (NORD)
• Others

Magazines

• Rare Disease Report
• Pharmaceutical Technology
• BioPharma Dive
• Others

Journals

• Journal of Allergy and Clinical Immunology
• Allergy, Asthma & Clinical Immunology
• Orphanet Journal of Rare Diseases
• Others

Newspapers

• The New York Times
• The Wall Street Journal
• USA Today
• The Guardian
• Others

Associations

• US Hereditary Angioedema Association (HAEA)
• Hereditary Angioedema International (HAEi)
• European Academy of Allergy and Clinical Immunology (EAACI)
• Others

Public Domain Sources

• World Health Organization (WHO)
• National Institutes of Health (NIH)
• Centers for Disease Control and Prevention (CDC)
• Others

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of information for last 8 years